deltatrials
Completed PHASE3 INTERVENTIONAL 4-arm NCT03096834

A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies

A 12-week Double-blind, Randomized, Multicenter Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous 140 mg AMG 334 Against Placebo in Adult Episodic Migraine Patients Who Have Failed 2-4 Prophylactic Treatments (LIBERTY)

Sponsor: Novartis Pharmaceuticals

Conditions Episodic Migraine
Interventions AMG334 (70 mg) Pre-Filled Syringe (PFS) Placebo Pre-Filled Syringe (PFS)
Updated 27 times since 2017 Last updated: Feb 23, 2022 Started: Mar 20, 2017 Primary completion: Jan 18, 2018 Completion: Jan 28, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Episodic Migraine and is currently completed. Novartis Pharmaceuticals leads this study, which shows 27 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~May 2017 – ~Jul 2017 · 2 months · monthly snapshot~Jul 2017 – ~Dec 2017 · 5 months · monthly snapshot~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Nov 2019 · 10 months · monthly snapshot~Nov 2019 – ~Jun 2020 · 7 months · monthly snapshot~Jun 2020 – ~Oct 2020 · 4 months · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

27 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE3

  5. Mar 2022 — Apr 2022 [monthly]

    Completed PHASE3

▶ Show 22 earlier versions

  1. Jan 2022 — Mar 2022 [monthly]

    Completed PHASE3

  2. Sep 2021 — Jan 2022 [monthly]

    Completed PHASE3

  3. Jun 2021 — Sep 2021 [monthly]

    Completed PHASE3

  4. May 2021 — Jun 2021 [monthly]

    Completed PHASE3

  5. Mar 2021 — May 2021 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  6. Feb 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE3

  7. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE3

  8. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  9. Nov 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE3

  10. Oct 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE3

  11. Jun 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE3

  12. Nov 2019 — Jun 2020 [monthly]

    Active Not Recruiting PHASE3

  13. Jan 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE3

  14. Nov 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE3

  15. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  16. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  17. Jul 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  18. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

    Status: Active Not Recruiting → Recruiting

  19. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  20. Dec 2017 — Mar 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  21. Jul 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  22. May 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

    First recorded

Mar 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, Greece , Bad Zurzach, Switzerland , Barcelona, Spain , Berlin, Germany , Bielefeld, Germany , Bochum, Germany , Bologna, Italy , Brighton, United Kingdom , Brussels, Belgium , Czech Republic, Czechia and 46 more locations